AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21276217 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for primary prevention of WMSD (six consecutive weekly sessions)
Number of subjects: 101
Study 21276217 — intervention group
Group type: COMPARATOR
Intervention: General health education (identical schedule to intervention group)
Number of subjects: 101
Study 19550287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel (0.001, 0.002, 0.005, or 0.02%)
Number of subjects: 119
Study 19550287 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 119
Study 19550287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel (0.02%)
Number of subjects: 119
Study 19550287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel
Number of subjects: 119
Study 17761367 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 13
Study 17761367 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 13
Study 15489632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hypotension (all ED SBP <100 mmHg for > or =60 min)
Number of subjects: 190
Study 15489632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest ED systolic blood pressure (SBP)
Number of subjects: 190
Study 15489632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hypotension
Number of subjects: 190
Study 15489632 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for signs and symptoms of shock
Number of subjects: 190
Study 15489632 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality rate
Number of subjects: 190
Study 11431597 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable insulin pump
Number of subjects: 10
Study 11431597 — intervention group
Group type: COMPARATOR
Intervention: Non-programmable insulin pump
Number of subjects: 10
Study 9685793 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Naclof)
Number of subjects: 64
Study 9685793 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 64
Study 8090301 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 2 mg (group F)
Number of subjects: 86
Study 8090301 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg (group T)
Number of subjects: 86
Study 2680793 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 151
Study 2680793 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 151
Study 2680793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Omeprazole and Ranitidine
Number of subjects: 151
Study 2680793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 151
Study 62161 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 47
Study 62161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31115844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus everolimus
Number of subjects: 133
Study 31115844 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine monotherapy
Number of subjects: 133
Study 29161288 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc with darunavir/ritonavir qd
Number of subjects: 115
Study 29161288 — intervention group
Group type: COMPARATOR
Intervention: Continuation of current ART
Number of subjects: 115
Study 24379454 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized music therapy anger management program
Number of subjects: 14
Study 24379454 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 14
Study 24123845 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone and Nestorone treatment after 4 weeks
Number of subjects: 0
Study 24123845 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Nestorone concentrations
Number of subjects: 0
Study 24123845 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum testosterone concentrations
Number of subjects: 0
Study 24123845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early suppression of gonadotropins
Number of subjects: 0
Study 21904235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 60
Study 21904235 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (SS)
Number of subjects: 60
Study 21904235 — intervention group
Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 60
Study 17881423 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 4
Study 17881423 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 4
Study 17881423 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-Normal Saline (2NS)
Number of subjects: 4
Study 17881423 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS) at home testing
Number of subjects: 4
Study 16055070 — intervention group
Group type: EXPERIMENTAL
Intervention: Free sorting task of material samples
Number of subjects: 124
Study 16055070 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical measurements of compressibility and roughness
Number of subjects: 124
Study 12847153 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic cholinergic terminal density measured with [123I]IBVM
Number of subjects: 13
Study 12847153 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal monoaminergic terminal density measured with [11C]DTBZ
Number of subjects: 13
Study 12847153 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects scanned with [123I]IBVM
Number of subjects: 13
Study 12847153 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects scanned with [11C]DTBZ
Number of subjects: 13
Study 10960942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin
Number of subjects: 0
Study 10960942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin regimens
Number of subjects: 0
Study 10960942 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study 8618474 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ara-C (HIDAC)
Number of subjects: 0
Study 8618474 — intervention group
Group type: COMPARATOR
Intervention: Standard induction treatment (implied control)
Number of subjects: 0
Study 1579228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal thyrotropin-releasing hormone (TRH)
Number of subjects: 36
Study 1579228 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study 4081627 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (1 mg/kg/h for 60 min, then 2 mg/kg/h until 180 min)
Number of subjects: 12
Study 4081627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4081627 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 12
Study 29078054 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Option Grid decision aids for Breast cancer, PSA, and Statins
Number of subjects: 626
Study 29078054 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Option Grid decision aids
Number of subjects: 626
Study 27160380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 500 lsu/day for 1 year (Group 3)
Number of subjects: 79
Study 27160380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 1000 lsu/day for 6 months followed by 250 lsu/day for 6 months (Group 4)
Number of subjects: 79
Study 27160380 — intervention group
Group type: COMPARATOR
Intervention: Control Group 1 (blank)
Number of subjects: 79
Study 27160380 — intervention group
Group type: COMPARATOR
Intervention: Control Group 2 (250 lsu/day for 1 year)
Number of subjects: 79
Study 25345483 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach for hip replacement
Number of subjects: 0
Study 25345483 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach for hip replacement
Number of subjects: 0
Study 23377602 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Token Economy (STTE)
Number of subjects: 44
Study 23377602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 20493637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 IU
Number of subjects: 24
Study 20493637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18634956 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-reflexotherapy intervention (NRT) - 2 treatments, one immediately after baseline assessment and another 45 days later.
Number of subjects: 51
Study 18634956 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (control group) - placement of epidermal devices within a 5-cm radius of target zones.
Number of subjects: 51
Study 16237621 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training exercise at the ventilatory threshold (VT) intensity for 12 weeks in T-CHD group
Number of subjects: 17
Study 16237621 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 17
Study 12081734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for abdominal aortic aneurysm (AAA)
Number of subjects: 6058
Study 12081734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 6058
Study 9931835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical methods for thromboembolism prevention (intermittent pneumatic compression, A-V impulse systems, ankle motion devices)
Number of subjects: 0
Study 9931835 — intervention group
Group type: COMPARATOR
Intervention: Conventional prevention (pharmacological and physical)
Number of subjects: 0
Study 9931835 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional prophylaxis supplemented with mechanical prophylaxis
Number of subjects: 0
Study 8564883 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg for females, 80 mg for males)
Number of subjects: 9
Study 8564883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8564883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (5 degrees C)
Number of subjects: 9
Study 12282175 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of RU 486 + 500 mg of sulprostone (Nalador) administered intramuscularly
Number of subjects: 354
Study 12282175 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 alone
Number of subjects: 354
Study 12282175 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete protocol (RU 486 + sulprostone)
Number of subjects: 354
Study 12282175 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 354
Study 364625 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 50
Study 364625 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy with pyloroplasty (SV + P)
Number of subjects: 50
Study 6459357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 60 micrograms ipratropium bromide and 200 micrograms of fenoterol
Number of subjects: 18
Study 6459357 — intervention group
Group type: COMPARATOR
Intervention: Lower dose combinations or either drug alone
Number of subjects: 18
Study 30786902 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 1+FUN intervention (ten-session intervention over approximately six months)
Number of subjects: 204
Study 30786902 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 1+FUN intervention
Number of subjects: 204
Study 30786902 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention for one year)
Number of subjects: 204
Study 30526600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of total physical activity (PA)
Number of subjects: 600
Study 30526600 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 600
Study 30526600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (SB)
Number of subjects: 600
Study 30526600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (SB) in combined model
Number of subjects: 600
Study 30526600 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 600
Study 30526600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI or FMI
Number of subjects: 600
Study 27567063 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled motivation for healthy eating
Number of subjects: 90
Study 27567063 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation for healthy eating
Number of subjects: 90
Study 24473704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation for 8 weeks
Number of subjects: 58
Study 24473704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (Group A)
Number of subjects: 58
Study 24473704 — intervention group
Group type: COMPARATOR
Intervention: No zinc supplementation (Group B)
Number of subjects: 58
Study 20835926 — intervention group
Group type: COMPARATOR
Intervention: Esophageal stenting alone (Group I)
Number of subjects: 84
Study 20835926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of stenting and external beam radiotherapy (Group II)
Number of subjects: 84
Study 20835926 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study 20835926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (after radiotherapy)
Number of subjects: 84
Study 21146675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (started after surgery for 30 days) + Aspirin 81 mg daily
Number of subjects: 100
Study 21146675 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Aspirin 81 mg daily
Number of subjects: 100
Study 21146675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin 81 mg daily
Number of subjects: 100
Study 17923056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate treatment
Number of subjects: 52
Study 17923056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15670002 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of caloric intake (mean intake close to prescribed intake)
Number of subjects: 62
Study 15670002 — intervention group
Group type: COMPARATOR
Intervention: Tertiles of caloric intake
Number of subjects: 62
Study 11915041 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose peginterferon alfa-2b (3 microg/kg for 1 week, 1.5 microg/kg for 3 weeks, and 1.0 microg/kg for 44 weeks) plus 800 mg ribavirin daily
Number of subjects: 55
Study 11915041 — intervention group
Group type: COMPARATOR
Intervention: Low dose peginterferon alfa-2b (0.5 microg/kg for 48 weeks) plus 800 mg ribavirin daily
Number of subjects: 55
Study 11915041 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose peginterferon alfa-2b
Number of subjects: 55
Study 9814337 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment teaching method
Number of subjects: 74
Study 9814337 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 74
Study 9373378 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support specific to exercise
Number of subjects: 269
Study 9373378 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial support from exercise staff
Number of subjects: 269
Study 9373378 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from family and friends and exercise staff at Month 6
Number of subjects: 269
Study 9373378 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programs
Number of subjects: 269
Study 9373378 — intervention group
Group type: EXPERIMENTAL
Intervention: Divorced nonsmokers
Number of subjects: 269
Study 2503018 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 200 mg three times daily with GTN 20 mg transdermal/24 h
Number of subjects: 8
Study 2503018 — intervention group
Group type: COMPARATOR
Intervention: Placebo with GTN 20 mg transdermal/24 h
Number of subjects: 8
Study 322243 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg daily)
Number of subjects: 28
Study 322243 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.6 g daily)
Number of subjects: 28
Study 31101083 — intervention group
Group type: EXPERIMENTAL
Intervention: SpHb monitoring
Number of subjects: 69
Study 31101083 — intervention group
Group type: COMPARATOR
Intervention: Standard-care (without SpHb monitoring)
Number of subjects: 69
Study 27890648 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (150 mg, twice a day for 12 weeks)
Number of subjects: 65
Study 27890648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26445318 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a 12-week supervised exercise programme
Number of subjects: 80
Study 26445318 — intervention group
Group type: COMPARATOR
Intervention: Usual care (compression only)
Number of subjects: 80
Study 23978323 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 145
Study 23978323 — intervention group
Group type: COMPARATOR
Intervention: Let's Talk About the Children (LTC)
Number of subjects: 145
Study 21245130 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration (HDF)
Number of subjects: 69
Study 21245130 — intervention group
Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 69
Study 19817198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy after selective posterior rhizotomy (SPR)
Number of subjects: 226
Study 19817198 — intervention group
Group type: COMPARATOR
Intervention: Selective posterior rhizotomy (SPR) only (Control)
Number of subjects: 226
Study 18184041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg/day for 3 weeks)
Number of subjects: 63
Study 18184041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 15066870 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix
Number of subjects: 49
Study 15066870 — intervention group
Group type: COMPARATOR
Intervention: M‐M‐R II
Number of subjects: 49
Study 10677821 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 0
Study 10677821 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI
Number of subjects: 0
Study 9355902 — intervention group
Group type: EXPERIMENTAL
Intervention: Abl+Pm (AV junction ablation and DDDR mode-switching pacemaker)
Number of subjects: 43
Study 9355902 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (Control)
Number of subjects: 43
Study 7692455 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (daily infusions of 6 hours)
Number of subjects: 267
Study 7692455 — intervention group
Group type: COMPARATOR
Intervention: PGE1 (2 x 2 hours infusions)
Number of subjects: 267
Study 7692455 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 267
Study 7692455 — intervention group
Group type: COMPARATOR
Intervention: PGE1
Number of subjects: 267
Study 3513518 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 14
Study 3513518 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg)
Number of subjects: 14
Study 3513518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Propranolol
Number of subjects: 14
Study 3513518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31488098 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified milk with 1.2 mg/100 mL of iron
Number of subjects: 133
Study 31488098 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified milk with 0.4 mg/100 mL of iron
Number of subjects: 133
Study 31488098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (1.2 mg and 0.4 mg of iron)
Number of subjects: 133
Study 27037849 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI target biopsy
Number of subjects: 138
Study 27037849 — intervention group
Group type: COMPARATOR
Intervention: Regular biopsy
Number of subjects: 138
Study 26565082 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium bifidum W23, Bifidobacterium animalis subsp. lactis W52, Lactococcus lactis W58, EcologicPanda)
Number of subjects: 0
Study 26565082 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0
Study 23711288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dearterialization (with Doppler guidance and mucopexy)
Number of subjects: 40
Study 23711288 — intervention group
Group type: COMPARATOR
Intervention: Haemorrhoidectomy
Number of subjects: 40
Study 21261482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 82
Study 21261482 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-formed retainer
Number of subjects: 82
Study 18188489 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT‐O procedure
Number of subjects: 120
Study 18188489 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarc procedure
Number of subjects: 120
Study 18188489 — intervention group
Group type: COMPARATOR
Intervention: Inside-out procedure
Number of subjects: 120
Study 18188489 — intervention group
Group type: COMPARATOR
Intervention: Outside-in procedure
Number of subjects: 120
Study 16484822 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous whole blood (AWB) injections, 8 weekly intramuscular injections
Number of subjects: 56
Study 16484822 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study 12635675 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% aminocaproic acid (ACA) in CPM gel
Number of subjects: 132
Study 12635675 — intervention group
Group type: COMPARATOR
Intervention: cycloplegic drops only
Number of subjects: 132
Study 12635675 — intervention group
Group type: COMPARATOR
Intervention: 2% carboxy polymethylene (CPM) gel as placebo
Number of subjects: 132
Study 10372738 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH + DDAVP
Number of subjects: 16
Study 10372738 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH
Number of subjects: 16
Study 10372738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8669413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fiber diet followed by labeled low-fiber test meal
Number of subjects: 6